Exelixis (EXEL) Misses Q1 EPS by 6c, Misses on Revenue

Go back to Exelixis (EXEL) Misses Q1 EPS by 6c, Misses on Revenue

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

April 30, 2024 4:05 PM EDT

- Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million -

- Restructuring Expenses of $32.8 million Recorded -

- GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.17 -

- Conference Call and Webcast Today at 5:00 PM Eastern Time -

ALAMEDA, Calif.--(BUSINESS... More